Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective

Background: Tyrosine kinase inhibitors (TKIs) are the standard-of-care treatment for chronic myeloid leukemia in chronic phase (CML-CP). Despite advances in therapy, there remains a proportion of patients with CML-CP that are refractory/intolerant to TKIs, and these patients cycle through multiple l...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Ehab L., Maegawa, Rodrigo, Latremouille-Viau, Dominick, Rossi, Carmine, Guérin, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353133/
https://www.ncbi.nlm.nih.gov/pubmed/35979529
http://dx.doi.org/10.36469/001c.36976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353133/
https://www.ncbi.nlm.nih.gov/pubmed/35979529
http://dx.doi.org/10.36469/001c.36976

Ejemplares similares